November 12th – 18th is Antibiotic Awareness Week
Antibiotic resistance is a threat to public health with multi-drug resistant bacterial infections becoming increasingly common in the hospital and community setting. Spero is committed to developing new treatment to address the critical unmet need of drug-resistant infections.
Leading Product Candidates
Spero Therapeutics is developing a portfolio of novel product candidates with the potential for meaningful patient impact and significant commercial applications. Our candidates are designed to treat MDR bacterial infections in both the hospital and community settings.